Who Owns Benadryl?

Benadryl operates under Johnson & Johnson's sustainability framework, implementing environmental initiatives and ethical business practices while maintaining its position as a leading antihistamine brand. The company has committed to achieving net-zero carbon emissions across its operations by 2045.

Environmental Sustainability: Johnson & Johnson has invested in renewable energy for production facilities, with over 20% of its electricity coming from renewable sources as of 2025. Benadryl packaging has been redesigned to incorporate more recycled materials and reduce plastic waste, aligning with Johnson & Johnson's goal to make all packaging recyclable, reusable, or compostable by 2025.

Sustainable Sourcing and Supply Chain: Benadryl ingredients are sourced through Johnson & Johnson's responsible sourcing programs, which require suppliers to meet environmental and ethical standards. The company conducts supplier audits to verify compliance with labor standards and environmental regulations throughout the pharmaceutical supply chain.

Ethical Research and Development: Benadryl benefits from Johnson & Johnson's clinical trial standards, including informed consent processes and independent ethics review boards for pharmaceutical research.

Benadryl has received recognition for its effectiveness in allergy relief treatment and consumer trust, though recent safety concerns have complicated its reputation. The brand ranks among the most recognized over-the-counter allergy medications in consumer surveys.

Consumer Trust and Brand Recognition: Benadryl has been recognized as a trusted allergy relief brand in consumer surveys, reflecting decades of established use for treating allergic reactions, itching, and cold symptoms.

Healthcare Professional Endorsements: Benadryl has received endorsements from allergists, pediatricians, and family physicians for its effectiveness in treating allergic conditions, though many now recommend it selectively given newer alternatives.

Product Quality and Safety Standards: Benadryl adheres to FDA regulations and Good Manufacturing Practices, which regulatory bodies and quality organizations have acknowledged.

Recent safety concerns about diphenhydramine's side effects and potential long-term health impacts have created challenges for Benadryl's reputation, tempering its consideration for consumer safety recognition even as it continues to receive credit for treatment effectiveness.

Benadryl has faced controversies related to safety concerns, particularly regarding diphenhydramine side effects and potential cognitive impacts, leading to increased scrutiny from healthcare professionals and regulatory bodies.

Diphenhydramine Safety Concerns (2025): Major healthcare organizations and medical journals have raised concerns about diphenhydramine's safety profile, particularly its effects on cognitive function and fall risk in older adults. The American Academy of Ophthalmology and World Allergy Organization have published statements suggesting that older antihistamines like Benadryl should be avoided due to risks of grogginess, cognitive impairment, and increased fall risk in elderly patients.

New York Times Investigation (July 2025): The New York Times published an investigation highlighting diphenhydramine's potential harms, including cognitive side effects and increased risk of falls and car accidents, citing medical experts who suggested moving away from older antihistamines like Benadryl.

FDA Safety Warnings (2025): The FDA issued strengthened warnings about serious problems with high doses of diphenhydramine, particularly regarding cardiac effects and central nervous system depression, increasing regulatory scrutiny of Benadryl's safety labeling.

TikTok Benadryl Challenge Controversy: Benadryl faced criticism regarding its association with the dangerous TikTok "Benadryl Challenge" trend, where young people intentionally misused the medication to experience its sedative effects. The American Academy of Allergy, Asthma & Immunology issued warnings about this trend.

Cognitive Impact Research: Scientific evidence published in medical journals suggests that regular diphenhydramine use may contribute to cognitive decline and increased dementia risk in older adults, leading healthcare professionals to recommend newer antihistamine alternatives for this population.

Current Status: As of 2026, Benadryl remains available over the counter in the United States. The FDA has not withdrawn approval or mandated a recall, but updated labeling now more prominently warns against use in elderly patients and against high-dose or off-label use. Johnson & Johnson continues to market Benadryl alongside newer, non-drowsy antihistamine brands in its portfolio.